AccMed Accelerators for Medicine

Slides:



Advertisements
Similar presentations
Ribbon Electron Beam Profile Monitor For Bunched Beam Tomography Muons, Inc. Innovation in research.
Advertisements

Energy deposition and neutron background studies for a low energy proton therapy facility Roxana Rata*, Roger Barlow* * International Institute for Accelerator.
An Advanced Linear Accelerator Facility for Microelectronic Dose Rate Studies P.E. Sokol and S.Y.Lee Indiana University.
Benefits of Radiation in Every Day Life. Beneficial Uses of Radiation Medical Diagnoses and Treatment Research Applications Industrial/Manufacturing Applications.
Tumour Therapy with Particle Beams Claus Grupen University of Siegen, Germany [physics/ ] Phy 224B Chapter 20: Applications of Nuclear Physics 24.
ECPM 2006, Nice, France, 2-4 November DESIGN STUDIES OF THE 300AMEV SUPERCONDUCTING CYCLOTRON FOR HADRONTHERAPY Mario Maggiore Laboratori Nazionali.
Study of the fragmentation of Carbon ions for medical applications Protons (hadrons in general) especially suitable for deep-sited tumors (brain, neck.
O Level Physics Chapter :25: Use of Radioactivity
Radiation oncology at JINR in brief Dzhelepov Laboratory of Nuclear Problems Joint Institute for Nuclear Research, Dubna, Russia  Accelerator technique.
P4: Radiation for Life Lesson 13: Treatment (part 1)
BIOLOGICAL EFFICIENCY OF A THERAPEUTIC PROTON BEAM: A STUDY OF HUMAN MELANOMA CELL LINE I. Petrović 1, A. Ristić-Fira 1, D. Todorović 1, L. Korićanac 1,
ARDENT MEETING Andrej Sipaj June 13 th, ABOUT ME  Born and raised in Slovakia  Studied: BEng in Mechanical Engineering at UOIT, Canada MASc in.
PAMELA Contact Author: CONFORM is an RCUK-funded Basic Technology Programme PAMELA: Concepts Particle Accelerator for MEdicaL Applications K.Peach(JAI,
A (Quick) Survey of (Some) Medical Accelerators Dr. Todd Satogata Brookhaven National Laboratory SUNY Stony Brook PHY 684 – September 5, 2007  The NASA.
Nuclear Medicine Olivia Nicholson Sannhi Pham Alex Bynum Ryan Hadfeild Olivia Nicholson.
FFAG Fixed Field Alternating Gradient synchrotrons, FFAGs, combine some of the main advantages of both cyclotrons and synchrotrons:  Fixed magnetic field.
FFAG Tune-stabilized, Linear-field Nonscaling FFAG Lattice Design C. Johnstone, Fermilab S. Koscielniak, TRIUMF FFAG07 April 12-17, 2007 LPSC, Grenoble,
THE TOP-IMPLART PROJECT Concetta Ronsivalle,Mariano Carpanese, Giovanni Messina, Luigi Picardi, Sandro Sandri (ENEA C.R. Frascati, Frascati (Roma)) Carmela.
Inertial Electrostatic Confinement Fusion Reactor Liquid Cooled Ion Accelerating Grid Design A. Seltzman, Georgia Institute of Technology Abstract: Reactor.
Response of the sensors to different doses from tests in Israel Radiotherapy is used as a treatment in around 50% of cancer cases in the UK. Predominantly,
Activities of Superconducting RF Accelerators at Nanjing University Sun An Proton Linear Accelerator Institute Institute of Energy Sciences, Nanjing University.
Using Radiation in Medicine. There are 3 main uses of radiation in medicine: Treatment Diagnosis Sterilization.
UK FFAG Plans Introduction to FFAGs Scaling vs non-scaling Non-scaling FFAGs Non-scaling POP Why the interest? UK plans.
Cancer Therapy and Imaging Cancer Therapy and Imaging Rob Edgecock STFC Rutherford Appleton Laboratory.
FFAG Tune-stabilized, Linear-field FFAG C. Johnstone, Fermilab S. Koscielniak, TRIUMF FFAG06 Japan f Fermilab.
RF Development for ESS Roger Ruber and Volker Ziemann Uppsala Universitet 4 Dec Dec-20091RR+VZ: ESS RF Development.
Production of innovative radionuclides at ARRONAX and 211 At RIT F. Haddad GIP ARRONAX.
USE OF GEANT4 CODE FOR VALIDATION OF RADIOBIOLOGICAL PARAMETERS OBTAINED AFTER PROTON AND CARBON IRRADIATIONS OF MELANOMA CELLS Ivan Petrović 1, Giuseppe.
RADIATION THERAPY By: Zach Liss. How does Radiation Therapy Work? Uses high-energy radiation to shrink tumors and kill cancer cells by damaging the DNA.
3 Medical uses of Radiation
Nuclear Chemistry: The Heart of Matter. 2 Radioisotopes Radioactive decay Radioactive decay – Many isotopes are unstable – Many isotopes are unstable.
ENLIGHT,12/2/20021 Health and Science, can CERN contribute? The Mission of CERN (1954): “The Organization shall provide for collaboration among European.
Knowledge Transfer Accelerating Innovation. slide 1 The Knowledge Transfer Group at the HR Induction Program (session II) 6 th September 2011 Enrico Chesta.
Medical Physics & Cyclotrons Dr. Benito de Celis Alonso 1,2 1 FCFM-BUAP 2 Fundación para el Desarrollo Carlos Sigüenza
The Australian Hadron Therapy and Research Facility.
9.2 Nuclear Fission and Fusion I CAN: -RECOGNIZE THAT THE STRONG NUCLEAR FORCE IS THE ATTRACTIVE FORCE THAT BINDS PROTONS AND NEUTRONS TOGETHER IN THE.
Dangers Of Radiation Radiation is usually ionizing meaning it can remove electron from atoms. This makes them radioactive and they give of radiation.
Varian Medical Systems
HADRONTHERAPY IN ROMANIA NICOLAE IOAN VERGA M.D., Ph.D., D.Sc. “CAROL DAVILA” UNIVERSITY OF MEDICINE AND PHARMACY, ROMANIAN SOCIETY OF HADRONTHERAPY BUCHAREST,
1 RHIC NSRL LINAC Booster AGS Tandems STAR 6:00 o’clock PHENIX 8:00 o’clock 10:00 o’clock Polarized Jet Target 12:00 o’clock RF 4:00 o’clock (AnDY, CeC)
Beam dynamics and linac optics studies for medical proton accelerators
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” September 2012, Saint-Petersburg Proton Radiation.
April 17, Dejan TrbojevicFFAG07 -Non-Scaling FFAG gantries1 Non-Scaling FFAG Gantries Introduction: Motives: The most challenging problem in the carbon/proton.
Plans and Activities at CERN
5.5 Medical Applications Using Radioactivity
J Cho, G Ibbott, M Kerr, R Amos, and O Mawlawi
Lecture 1: Definition of Nanomedicine and Nanotechnology
FREIA Division for Accelerator and Instrumentation Development
Understanding Radiation Therapy Lecturer Radiological Science
Medical physics AMMAR ALHASAN University of Central Florida
Present and possible future schemes for hadron therapy linacs Alberto Degiovanni for the ADAM team HG2017 Workshop , Valencia.
Progress in the Application
Grzegorz Wrochna, PIMS kick-off CERN
Uses of radiation.
Extending intracranial treatment options with Leksell Gamma Knife® Icon™ Key Statements from Customer Perspective by University Medical Centre Mannheim.
Uppsala Commitment to ESS and FREIA Planning
MeV Ion Microbeams and Radiation Biology at the University of Surrey
The Chemical Context of Life
ESS RF Development at Uppsala University
Task 2.3 “Sustainability”
IONIZING RADIATION ….. a discussion of the health hazards associated with handling and use of materials capable of producing ionization of matter.
Chain Reactions Chain Reaction - the series of repeated fission reactions caused by the release of neutrons in each reaction.
Institute for Applied Physics National academy of sciences of Ukraine
Medical Imaging Imagining Modalities.
recent activities our company Jean Claude Le Scornet - Tomas JUNQUERA
Innovations in the Radiotherapy of Non–Small Cell Lung Cancer
Multiphysics Simulation Story: MRI Tumor-Tracked Cancer Treatment
Atomic structure.
Roger Ruber for the FREIA team 11 June 2013, Uppsala
Presentation transcript:

AccMed Accelerators for Medicine An application in response to the SSF call for proposals for Industrial Research Centres 4/11/2016 Tord Ekelöf FREIA-avdelningen

Tord Ekelöf FREIA-avdlningen Industry and Institution Partners Industry partners General Electric Healthcare Gems Pet Systems, Uppsala - PET cyclotrons Elekta Instrument, Uppsala - gamma therapy ScandiNova, Uppsala - high voltage pulse modulators Gammadata, Uppsala - radiation monitors Scnditronix Magnets, Vislanda - beam line magnets RFR Solutipons, Landskrona - stainless steel vacuum chambers Institution partners FREIA/Department of Physics and Astronomy, UU – Center Leader [huvudsökande] - liquid He cryogenics, vacuum and solid state radiofrequency high power sources, high vacuum, process control, GHz linac development, dosimetry Department of Genetics and Pathology, UU and Academic Hospital - medical radiation physics and radiobiology Center for Medical Technology, UU - diagnostics instrumentation UU Innovation - Intellectual Property regulation Skandion Clinic - clinical proton therapy Department of Oncology and Pathology, Karolinska Institute - clinical oncology CERN ENLIGHT Medical accelerator project - superconducting cyclotron coils 4/11/2016 Tord Ekelöf FREIA-avdlningen

Tord Ekelöf FREIA-avdelningen Main objective of AccMed: To apply advanced accelerator and instrumentation techniques, developed for cutting-edge fundamental research in Big Science, for the urgent need of improving radionuclide availability for clinical PET diagnostics by designing and fabricating a prototype of a superconducting 15 MeV cyclotron for radionuclide production and to work towards the realization of a prototype for a combined superconducting cyclotron and linear accelerator for carbon ions of 400 MeV/nucleon for cancer therapy. 4/11/2016 Tord Ekelöf FREIA-avdelningen

Tord Ekelöf FREIA-avdelningen Superconducting cyclotron for radionuclide production The AccMed project will have as a first goal to develop advanced equipment that is smaller, lighter and less costly than the equipment presently in use for radionuclide production, such that such equipment can be acquired by more hospitals than just a few and make possible the use of more short-lived isotopes in these hospitals, implying that the irradiation dose to the patient during PET diagnostics can be significantly decreased. This will enable direct local production of radionuclides like F18 and Tc99m in the hospital for nuclear medicine. In particular this will also eliminate the need for long distance transports of reactor produced radioactive Mo99/Tc99m generators. 4/11/2016 Tord Ekelöf FREIA-avdelningen

Tord Ekelöf FREIA-avdelningen Superconducting cyclotron with linac for carbon ion therapy The AccMed project will have as a second goal to develop advanced equipment that can be used to produce carbon-ion beams for cancer therapy using a cyclotron-linac (cyclinac) combination, which will make it possible to strictly limit the irradiation to the tumor only, implying that the damage to the surrounding healthy tissue during tumor irradiation will be significantly reduced. There is a rapidly growing interest in systems that treat cancer effectively with carbon ions, which is needed for so called radio resistant tumors (tumors more resistant than the surrounding healthy tissue, 5% of the cases) and for small tumors located near vital organs in the patient body. 4/11/2016 Tord Ekelöf FREIA-avdelningen

GEs MINItrace cyclotron for radioisotope production 18F-fluoride production Proton acceleration capability up to 9.6 MeV >99.9% beam extraction Two resonators, RF Power Generator Vertically oriented magnet design Self-diagnostics and embedded control technique High-grade radiation self-shielding Fully automated sequence Hollow-core, water-cooled copper conductor magnet coils Fixed-position, internally mounted ion source System dimensions Cyclotron including self-shield  Length 2100 mm (83 in)  Width 3600 mm (142 in)  Height 2100 mm (83 in)  Weight 50 350 kg (111 000 lbs) 4/11/2016 Tord Ekelöf FREIA-avdelningen

Proton linac and Carbon-ion cyclinac* *cyclinac = cyclotron + linear accelerator Proton linac LIGHT Advantages of linac over cyclotron: 1. spot scanning (step and shoot) 2. volumetric multipainting (10-12 times)  3. tumor tracking (follow tumor movement) Cabon-ion cyclinac Advantages of carbon ions over protons: 1. Very sharp Bragg peak 2. 25 times higher ionization density 3. Causes clustered double strand-breaks in the cell nucleus and thereby kills radio resistant tumors (5% all tumors) 4. Small current enough spares healthy tissue 4/11/2016 Tord Ekelöf FREIA-avdelningen

Tord Ekelöf FREIA-avdelningen Relation of the project to state of the art in the area A prototype for a superconducting proton cyclotron for radioisotope production has been produced by a company Ionetix in the US and two more such prototypes are currently being designed by a company PMB Alcen in France. There is one company in Geneva AVO-ADAM which is currently producing a first linear accelerator LIGHT for proton therapy but, to our knowledge, no company is currently producing a prototype for a linear accelerator for carbon therapy. 4/11/2016 Tord Ekelöf FREIA-avdelningen

Tord Ekelöf FREIA-avdelningen Concluding remarks - AccMed has IRC a complete set of institution and industry partners with the required research competence in accelerators and radiobiology/medical radiation-physics and in industrial technology and marketing. - Neither of the two accelerators and methods are available on the commercial market, the PET SC cyclotron can be taken from design study to prototype fabrication and tests and to the market within the project period 6-8 years, the carbon cyclinac is a “disruptive” project and can be taken from design study to prototype fabrication and tests of some parts of the full scale cyclinac within the same period. - The AccMed SSF-IRC Centre will provide FREIA with a substantial project beyond spring 2019 (when the current ESS commitment will be finished) together with the other accelerator development project for CERN (LHC upgrade) and instrumentation projects for CERN, MAX-IV, ITER and ESS. 4/11/2016 Tord Ekelöf FREIA-avdelningen